A new method of measuring tumor progression offers prognostic implications for patients with head and neck squamous cell carcinoma experiencing treatment delays.

Conferences

Treatment with nivolumab reduced the risk of death and improved one-year overall survival (OS) compared with investigator’s choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma, according to clinical trial findings presented at the 2016 American Association for Cancer Research Annual Meeting (April 16-20; New Orleans, LA).

Read More

News

A new method of measuring tumor progression offers prognostic implications for patients with head and neck squamous cell carcinoma experiencing treatment delays.
Close and continuous monitoring is an acceptable approach to patient management of papillary microcarcinoma of the thyroid.
Treatment with everolimus may be associated with durable disease control in patients with advanced or recurrent thymoma or thymic carcinoma, according to a recent study.
Recent research has found that age-associated risk in papillary thyroid cancer is dependent on BRAF V600E or wild-type status.

Research in Review

A recent study suggests that immunotherapies targeting both PD-L1 and PD-L2 may enhance response rates for patients with head and neck squamous cell carcinoma (HNSCC), published in Clinical Cancer Research (published online June 2017; doi:10.1158/1078-0432.CCR-16-1761).

-----

Related Content

Read More

Research presented at the 2017 American Society of Clinical Oncology showed that although human papillomavirus (HPV) vaccine reduces the rate of oral HPV infection, the vaccine is still underutilized among teens and young adults.

-----

Related Content

Read More

PD-L1 expression may be a biomarker of local failure in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma following radiotherapy, according to research published in Clinical Cancer Research (published online May 2017; doi:10.1158/1078-0432.CCR-16-2586).

-----

Related Content

Read More

Patients aged 80 years or older with early-stage esophageal cancer who received treatment had an increased 5-year overall survival (OS) compared with those who received no treatment or observation alone, according to research published in the Journal of Thoracic Oncology (published online April 2017; doi:10.1016/j.jtho.2017.04.004).

-----

Read More

Subscribe to Head & Neck Cancer